Effect of Eicosapentaenoic Acid Supplementation on Paraoxonase 2 Gene Expression in Patients with Type 2 Diabetes Mellitus: a Randomized Double-blind Clinical Trial.
- Author:
Mohammad Hassan GOLZARI
1
;
Mohammad Hassan JAVANBAKHT
;
Ehsan GHAEDI
;
Hamed MOHAMMADI
;
Mahmoud DJALALI
Author Information
- Publication Type:Clinical Trial ; Randomized Controlled Trial ; Original Article
- Keywords: Eicosapentaenoic acid; Paraoxonase-2; Gene expression; Type 2 diabetes mellitus; Randomized Controlled Trial
- MeSH: Aryldialkylphosphatase*; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2*; Dyslipidemias; Eicosapentaenoic Acid*; Fasting; Fatty Acids, Unsaturated; Gene Expression*; Humans; Lipoproteins; Metabolic Diseases; Oxidative Stress; Up-Regulation
- From:Clinical Nutrition Research 2019;8(1):17-27
- CountryRepublic of Korea
- Language:English
- Abstract: Type 2 diabetes mellitus (T2DM) is recognized as one of the most prevalent metabolic diseases, and it is mostly associated with oxidative stress, atherosclerosis and dyslipidemia. Paraoxonase 2 (PON2) due to its antioxidant properties may play a role in the atherosclerosis development. Although long-chain omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) have been shown to reduce the risk of cardiovascular disease, the exact mechanism of action is still unknown. Our goal in this study was to determine the effect of EPA administration on gene expression of PON2 in patients with T2DM. Present study was a randomized, controlled double-blind trial. Thirty-six patients with T2DM were randomly allocated to receive 2 g/day EPA (n = 18) or placebo (n = 18) for 8 weeks. There were no significant differences between 2 groups concerning demographic or biochemical variables, and dietary intakes as well (p > 0.05). However, patients received EPA showed a significant increase in the gene expression of PON2 compared with placebo group (p = 0.027). In addition, high-density lipoprotein cholesterol increased and fasting blood sugar decreased significantly after EPA supplementation compared with control group. Taken together, supplementation with 2 g/day EPA could be atheroprotective via the upregulation of PON2 in patients with T2DM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03258840
